Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial completed Feb 2026 per sponsor site (est primary completion matches). No public readout found: results summaries link yields no content; AZ pipeline docs list as Phase II, data anticipated H2 2026; ClinicalTrials.gov no results posted. Evidence incomplete, no clear positive/negative framing.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed85% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial (NCT06299826/LUMINARA) completed primary data collection ~Feb 2026. No public top-line results, press release, or readout found framing outcome as positive/negative. AZ lists as ongoing in pipeline; results expected H2 2026. Preclinical/prior data positive but not trial-specific.
Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:19 PM
NO_DECISIONDismissed80% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout is publicly posted yet. Sponsor sources show LUMINARA/NCT06299826 is complete, but the patient summary page says no results documents have been posted, and AstraZeneca’s February 2026 appendix still lists data as anticipated in H2 2026.
Found Apr 3, 2026, 4:06 PMReviewed Apr 3, 2026, 4:47 PM
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout was found. The exact Phase 2b study is identified on ClinicalTrials.gov, but an independent 2026 report says AZD5462 data are due in H2 2026, and FDAAA TrialTracker still showed no actual results posted as of March 26, 2026. With no public interpretation for this exact trial, outcome cannot be classified positive or negative.
Found Apr 1, 2026, 7:07 PMReviewed Apr 1, 2026, 7:16 PM
ClinicalTrialsclinicaltrials.govDec 1, 2025, 12:00 AM
Study Details | NCT06299826 | A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
ClinicalTrials.gov identifies NCT06299826 as the Phase IIb AZD5462 trial in chronic heart failure, evaluating change from baseline in echocardiography parameters to Week 25.
Web Searchfiercebiotech.comFeb 10, 2026, 7:50 AM
AstraZeneca relaxed about relaxin drug's poor efficacy in phase 2 heart failure trial
Fierce Biotech reported that AstraZeneca is continuing AZD5462 and that data from the Phase 2b trial in stable chronic heart failure are due in the second half of 2026.
Web Searchfdaaa.trialstracker.netMar 26, 2026, 12:00 AM
NCT06299826: An ongoing trial by AstraZeneca
FDAAA TrialTracker listed the study as completed Feb. 10, 2026, but with Results Status 'Ongoing' and 'Actual reporting date: None' when last checked on March 26, 2026.